Use of oxazolidinone compound for resisting biofilm

A technology of oxazolidinone and compound, which is applied in the field of oxazolidinone compound anti-biofilm, can solve problems such as ignorance, prevent or inhibit the formation of bacterial biofilm, reduce the quality of extracellular matrix, reduce biomass and The effect of viable count

Active Publication Date: 2015-09-02
SICHUAN GOODDOCTOR PHARMA GRP +1
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, due to the particularity of bacterial biofilm in terms of morphology, structure, physiological and biochemical properties, etc., it is still unknown whether this typ

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of oxazolidinone compound for resisting biofilm
  • Use of oxazolidinone compound for resisting biofilm
  • Use of oxazolidinone compound for resisting biofilm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 Staphylococcus aureus MSSA, MRSA and clinical isolate biofilm phenotype

[0072] microplate method [1]、[2] The biofilm was cultured, and the number and activity of Staphylococcus aureus biofilm bacteria were detected by crystal violet and resazurin staining to detect the phenotypic mechanism of biofilm formation of MSSA, MRSA and clinical isolates.

[0073] MSSA strain ATCC25923 formed a mature biofilm at 24 hours, compared with the early biofilm formed at 6 hours, the biomass (Biomass) and the number of viable bacteria of the mature biofilm increased by 4.5 and 2.7 times, respectively. Compared with the early biofilm of MRSA strains ATCC33591 and ATCC43300, the mature biofilm had an increase of 7-8 times and 2-4 times in the biomass and number of viable bacteria of the biofilm. Mature biofilms formed by clinical isolates (Au-1, Au-2, and Au-3) showed similar trends, with 15-20 times more bacteria and 4.5-6 times more bacterial activity than 6h biofilms ( f...

Embodiment 2

[0075] The MIC of embodiment 2 medicine of the present invention, MBC and MBEC detect

[0076] The minimum inhibitory concentration (MIC) of FYL-67 or linezolid against planktonic Staphylococcus aureus was detected by the microdilution method recommended by NCCLS. The minimum bactericidal concentration (MBC) was determined by the double-dilution plate viable count method in broth, and the minimum biofilm eliminating concentration (MBEC) was determined by the colony count method after biofilm formation.

[0077] The in vitro activity results of FYL-67 against clinical isolates MSSA and MRSA are shown in Table 1.

[0078] Table 1

[0079]

[0080] From the results in Table 1, it can be known that the MIC value of FYL-67 to MRSA and MSSA ranges from 0.5-1ug / ml. The MBEC values ​​of FYL-67 and linezolid for MSSA and MRSA were between 128-256 mg / l and 256-516 mg / l, respectively. The MIC value of the control strain Staphylococcus aureus ATCC25923 to the antibiotic linezolid re...

Embodiment 3

[0081] The impact of embodiment 3FYL-67 on biofilm formation

[0082] The microplate method was used to cultivate the biofilm, and the effects of FYL-67 and linezolid on the formation of early biofilm and mature biofilm were detected by staining with crystal violet and resazurin, and linezolid was used as the control ( figure 2 and 3 ).

[0083] The early biofilm formed by ATCC25923 was treated with 1 / 8, 1 / 4, 1 / 2, 1MIC concentration of FYL-67 or linezolid, compared with the control group without drug treatment, the biomass of the early biofilm was reduced About 50%.

[0084]When 1 / 8-1 / 4MIC of FYL-67 or linezolid treated MRSA strains, the biomass did not decrease. However, FYL-67 reduced MRSA biomass by 20-25% and 63-72% at 1 / 2MIC and 1MIC, respectively. 1 / 2MIC and 1MIC linezolid treated MRSA early biofilm, and the biomass decreased by 10-15% and 59-63%, respectively. The early biofilms formed by the three clinical isolates had basically the same changes in biomass after ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention provides a use of an oxazolidinone compound shown in the formula I in preparation of a drug, a disinfectant or a daily chemical article for preventing or inhibiting bacterial biomembrane formation or removing a bacterial biofilm. The oxazolidinone compound can effectively prevent or inhibit bacterial biofilm formation or removing a bacterial biofilm, can effectively reduce biomass and viable count of a biofilm, has biofilm resistance activity obviously superior to that of a classical drug linezolid, and provides a better choice for treatment or prevention of biofilm-caused infection.

Description

technical field [0001] The invention relates to a new application of oxazolidinone compounds for anti-biofilm. Background technique [0002] Bacterial biofilm is one of the more common types of biofilm, also known as bacterial biofilm (Bacterial biofilm, BF), which means that bacteria adhere to the contact surface and secrete polysaccharide matrix, fibrin, lipoprotein, etc. A large number of bacterial aggregate membranes formed by surrounding itself, it is a life phenomenon that bacteria are conducive to survival in order to adapt to the natural environment, formed by the accumulation of microorganisms and their secretions. Bacterial biofilm is a special bacterial population structure, which is significantly different from planktonic bacteria in terms of its morphological structure, physiological and biochemical characteristics, pathogenicity, and sensitivity to environmental factors, especially for antibiotics and host immune systems. Strong resistance, leading to serious ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4439A61K31/422A61P31/04A01N43/76A01P1/00
Inventor 王震玲罗有福魏于全耿福能
Owner SICHUAN GOODDOCTOR PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap